fbpx
  • Home
  • Study Details
Open

LIPOSORBER LA-15 system for Adult and Pediatric FSGS

To evaluate the safety and efficacy of a device removing lipids from the blood using an apheresis device in treating primary FSGS

Age & Gender

  • 5 years ~ 75 years
  • Male, Female, Gender Inclusive

Visit Availability

  • Standard business hours (M-F, 8-5)

Location

North Carolina (Statewide)

What will be asked of you

When you or your child come for the LIPOSORBER apherisis procedure, we will ask questions and collect blood and urine samples. After the treatment is completed, you/your child will have 5 follow-up visits with physical exam, vitals and collection of blood and urine to learn about the long term effect of this treatment.

Incentives

$50 per visit

In-person visits : 18
Total length of participation : 24 months

Looking for Specific Volunteers

Able to participate:

  • you have primary FSGS (= not caused by another disease) and protein in the urine
  • You your kidney function is good (eGFR >= 60) and the treatments you have had so far are not successful or you don't tolerate them
  • or you have received a kidney transplant and you have protein in the urine

Not eligible if:

  • pregnant or lactating or planning to become pregnant
  • your child wight less than 39.7 lbs (18 kg)
  • you do not want to come for the follow-up visits

Contact the Team

Visit Location

100% Remote (online, phone, text)

Additional Study Information

Principal Investigator

Koyal Jain
Medicine-Nephrology

Study Type

Clinical or Medical

Study Topics

Kidneys and Liver

IRB Number

19-1585

ClinicalTrials.gov

NCT04065438; NCT02235857

logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research
Research for Me logo

Copyright © 2013-2020 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.